Whitehawk Therapeutics, Inc. (WHWK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $180.57M
Last updated: Nov 17, 2026 at 11:04 AM ET
Whitehawk Therapeutics, Inc. (WHWK) Earnings: Report Dates and Results
Whitehawk Therapeutics (WHWK) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Whitehawk Therapeutics reported EPS of -$0.23, above the -$0.24 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
WHWK has an expected report date of Mar 10, 2027.
WHWK Earnings Call
The latest WHWK earnings call transcript on file is labeled 2024Q4.
Read the 2024Q4 transcriptEarnings History
Of the 26 quarters below that had an estimate, WHWK beat 15, missed 8 and matched 3. The widest gap in the table came in the quarter ended Jun 30, 2025, when EPS landed 255.10% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.23 | -$0.24 | -$0.27 - -$0.21 | +4.17% | Beat | N/A | 4 | 2 up, 0 down | Nov 9, 2026 | N/A |
| Jun 30, 2026 | -$0.20 | -$0.30 | N/A | +33.33% | Beat | N/A | 4 | N/A | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$0.32 | -$0.33 | -$0.36 - -$0.29 | +3.03% | Beat | N/A | 3 | 0 up, 2 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$0.34 | -$0.69 | N/A | +50.74% | Beat | N/A | 2 | 0 up, 1 down | Mar 12, 2026 | N/A |
| Sep 30, 2025 | -$0.25 | -$0.22 | N/A | -13.64% | Miss | N/A | 1 | 3 up, 0 down | Nov 6, 2025 | N/A |
| Jun 30, 2025 | -$0.76 | $0.49 | N/A | -255.10% | Miss | N/A | 1 | 3 up, 0 down | Aug 7, 2025 | N/A |
| Mar 31, 2025 | -$0.36 | -$0.23 | N/A | -56.52% | Miss | N/A | N/A | N/A | May 8, 2025 | $7.14M |
| Dec 31, 2024 | -$0.67 | -$0.21 | N/A | -219.05% | Miss | N/A | N/A | N/A | Mar 18, 2025 | $7.24M |
| Sep 30, 2024 | -$0.37 | -$0.47 | N/A | +21.28% | Beat | N/A | N/A | N/A | Nov 6, 2024 | $7.21M |
| Jun 30, 2024 | -$0.54 | -$0.64 | N/A | +15.63% | Beat | N/A | N/A | N/A | Aug 7, 2024 | $6.18M |
| Mar 31, 2024 | -$0.68 | -$0.62 | N/A | -9.68% | Miss | N/A | N/A | N/A | May 8, 2024 | $5.35M |
| Dec 31, 2023 | -$0.60 | -$0.65 | N/A | +7.69% | Beat | N/A | N/A | N/A | Mar 13, 2024 | $6.33M |
| Sep 30, 2023 | -$0.60 | -$0.73 | N/A | +17.81% | Beat | N/A | N/A | N/A | Nov 8, 2023 | $5.96M |
| Jun 30, 2023 | -$0.67 | -$0.60 | N/A | -11.67% | Miss | N/A | N/A | N/A | Aug 9, 2023 | $6.20M |
| Mar 31, 2023 | -$0.57 | -$0.57 | N/A | 0.00% | In line | N/A | N/A | N/A | May 10, 2023 | $5.87M |
| Dec 31, 2022 | -$0.48 | -$0.72 | N/A | +33.33% | Beat | N/A | N/A | N/A | Mar 29, 2023 | $5.23M |
| Sep 30, 2022 | -$0.68 | -$0.75 | N/A | +9.33% | Beat | N/A | N/A | N/A | Nov 9, 2022 | $4.25M |
| Jun 30, 2022 | -$0.69 | -$0.73 | N/A | +5.48% | Beat | N/A | N/A | N/A | Aug 10, 2022 | $3.44M |
| Mar 31, 2022 | -$0.66 | -$0.68 | N/A | +2.94% | Beat | N/A | N/A | N/A | May 12, 2022 | $2.31M |
| Dec 31, 2021 | -$0.77 | -$0.77 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 17, 2022 | $1.00M |
| Sep 30, 2021 | -$1.42 | -$0.73 | N/A | -94.52% | Miss | N/A | N/A | N/A | Nov 10, 2021 | N/A |
| Jun 30, 2021 | -$1.35 | -$6.00 | N/A | +77.50% | Beat | -687.0% | N/A | N/A | Aug 11, 2021 | N/A |
| Mar 31, 2021 | -$0.09 | -$0.09 | N/A | 0.00% | In line | N/A | N/A | N/A | May 17, 2021 | $120000 |
| Dec 31, 2020 | -$0.10 | -$0.14 | N/A | +28.57% | Beat | N/A | N/A | N/A | Mar 11, 2021 | N/A |
| Sep 30, 2020 | -$0.12 | -$0.14 | N/A | +14.29% | Beat | N/A | N/A | N/A | Nov 10, 2020 | $231000 |
| Jun 30, 2020 | $0.23 | $0.27 | N/A | -14.81% | Miss | N/A | N/A | N/A | Aug 12, 2020 | $15.00M |
| Mar 31, 2020 | -$1.45 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2020 | N/A |
| Dec 31, 2019 | -$1.64 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 16, 2020 | N/A |
| Sep 30, 2019 | -$1.72 | N/A | N/A | N/A | N/A | -140.7% | N/A | N/A | Nov 7, 2019 | N/A |
| Jun 30, 2019 | -$2.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2019 | N/A |
| Mar 31, 2019 | -$3.14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2019 | N/A |
| Dec 31, 2018 | -$3.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 5, 2019 | $2144 |
| Sep 30, 2018 | $4.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 7, 2018 | $18.82M |
| Jun 30, 2018 | -$3.29 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2018 | $1.33M |
| Mar 31, 2018 | -$4.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2018 | N/A |
| Dec 31, 2017 | -$3.47 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 13, 2018 | N/A |
| Sep 30, 2017 | -$2.59 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 29, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.71, after -$2.26 the year before. It was -$6.06 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.71 | N/A |
| Dec 31, 2024 | -$2.26 | N/A |
| Dec 31, 2023 | -$2.44 | N/A |
| Dec 31, 2022 | -$2.51 | N/A |
| Dec 31, 2021 | -$3.63 | N/A |
| Dec 31, 2020 | -$1.44 | N/A |
| Dec 31, 2019 | -$8.60 | N/A |
| Dec 31, 2018 | -$6.33 | N/A |
| Dec 31, 2017 | -$6.06 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2024Q4 for the period ended Dec 31, 2024, runs about 2,900 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q4 | Dec 31, 2024 | 2,947 | 7 | |
| 2024Q2 | Jun 30, 2024 | 5,492 | 10 |
2024Q4 Earnings Call
Opening remarks
Audrey Gross Head of Corporate Communications Thank you. Good morning, and welcome to the Whitehawk Therapeutics conference call. We will be presenting slides as part of the live webcast of this call. Such slides will be posted on the Investor News page of the Whitehawk Therapeutics website at whitehawktx.com following the conference call. A reminder that statements made on the call today will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our annual and quarterly filings with the Securities and Exchange Commission, which can be found at www.sec.gov or on our website at whitehawktx.com. In addition, any forward-looking statements made on this call represent our views only as of today, March 19, 2025, and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. On the call today is Dr. Dave Lennon, our President and CEO; Scott Giacobello, our CFO; and Dr. David Dornan, our newly appointed CSO. Today, we will introduce Whitehawk Therapeutics and provide an overview of Q4 and full year 2024 financial results before turning the line open for questions. I'll now turn the call over to Dave. Dave?
Dave Lennon President and CEO Thank you, Audrey. Hello, everyone. Good morning, and thank you for being here. I'm Dave Lennon, the President and CEO of the newly launched Whitehawk Therapeutics. We are very excited about our transition from Aadi Biosciences to Whitehawk. I am eager to share our vision, strategy, and the opportunities we have to make a significant impact for patients through our advanced ADC portfolio. In December, we announced several strategic transactions, including the in-licensing of three ADCs from Wuxi Biologics, the divestiture of FYARRO to Kaken Pharmaceuticals, and a $100 million private investment that received approval in a special meeting of stockholders last month. As we move forward, Aadi Biosciences is now reorganized into two entities. After Kaken's acquisition of Aadi's subsidiary, they will now own the Aadi name, trademark, and the FYARRO business. Today, the Aadi Parent Company rebrands as Whitehawk Therapeutics, solidifying our focus on ADC development. While we remain grounded in our roots of using technology to enhance precision oncology therapies, Whitehawk presents several new distinctions. Aadi was previously centered on mTOR inhibition within rare cancer settings and was based on the foundation of a single commercial product. In contrast, Whitehawk is dedicated to rapidly advancing a multi-asset portfolio of cutting-edge ADC therapies designed to deliver meaningful improvements across various cancer populations.
Frequently Asked Questions About WHWK
When is Whitehawk Therapeutics's next earnings date?
Whitehawk Therapeutics's next earnings report is expected for Mar 10, 2027.
Did WHWK beat earnings estimates last quarter?
Yes. Whitehawk Therapeutics reported EPS of -$0.23 for the quarter ended Sep 30, 2026, above the -$0.24 estimate, a 4.17% surprise.
What EPS do analysts expect from WHWK next quarter?
The consensus EPS estimate for Whitehawk Therapeutics for the quarter ending Dec 31, 2026 is -$0.22 from 11 analysts, with estimates from -$0.25 to -$0.14.
How often does WHWK beat earnings estimates?
Whitehawk Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -56.63%.
WHWK pages: Overview, Earnings, Forecast, Financials, Competitors